These two main patient subsets did not differ significantly with regard to genetic abnormalities (cytogenetic abnormalities; NPM1 and Flt3 mutations) or AML cell differentiation (FAB classification, CD34 expression). This evidence concerns the gene FLT3 and acute myeloid leukemia.